INDUCTION OF HIGH-AFFINITY PAF RECEPTOR EXPRESSION DURING T-CELL ACTIVATION

被引:36
作者
CALABRESSE, C
NGUER, MC
PELLEGRINI, O
BENVENISTE, J
RICHARD, Y
THOMAS, Y
机构
[1] INSERM,U200,32 RUE CARNETS,F-92140 CLAMART,FRANCE
[2] UNIV PARIS SUD,U131,CLAMART,FRANCE
关键词
D O I
10.1002/eji.1830220604
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Activated human T cells via the CD2 or the CD3 pathways exhibited a higher capacity than resting T lymphocytes to incorporate and metabolize [H-3] paf-acether (paf) at 37-degrees-C. Resting T lymphocytes lacked specific binding capacity for paf, yet high-affinity paf receptors (paf-R) were induced on CD3- or CD2-dependent activation. This up-regulation in the number of paf-R became apparent by day 1 of culture, reached a maximum of about 25 000 sites cell by days 4 to 6 and subsequently declined. Interestingly, human recombinant interleukin-2 in. a dose-dependent manner prevented the decrease of high-affinity paf-R expression on T cells. By contrast, the receptor affinity was constant throughout the culture period. Thus, paf-R at different stages of T cell activation were indistinguishable with respect to receptor-ligand interaction, and differed only in their number. Together, these data demonstrate that after activation human T cells develop membrane high-affinity paf-binding sites. They also suggest for the first time that expression of the paf-R are coupled to T cell activation and/or differentiation.
引用
收藏
页码:1349 / 1355
页数:7
相关论文
共 54 条
  • [1] KINASES AND PHOSPHATASES IN T-CELL ACTIVATION
    ALEXANDER, DR
    CANTRELL, DA
    [J]. IMMUNOLOGY TODAY, 1989, 10 (06): : 200 - 205
  • [2] ARMITAGE RJ, 1990, J IMMUNOL, V144, P938
  • [3] BENSASSON SZ, 1990, J IMMUNOL, V145, P1127
  • [4] LEUKOCYTE-DEPENDENT HISTAMINE-RELEASE FROM RABBIT PLATELETS - ROLE OF IGE, BASOPHILS, AND A PLATELET-ACTIVATING FACTOR
    BENVENISTE, J
    HENSON, PM
    COCHRANE, CG
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1972, 136 (06) : 1356 - +
  • [5] BENVENISTE J, 1988, BIOL MEMBRANES ABERR, P73
  • [6] BIERER BE, 1989, IMMUNOL REV, V111, P212
  • [7] BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
  • [8] CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974
  • [9] DULIOUST A, 1988, J IMMUNOL, V140, P240
  • [10] DULIOUST A, 1990, J IMMUNOL, V144, P3123